1. Cristiana Moliterni, V. M. Luigi Cattivelli, P. Ranalli and Giuseppe Mandolino. 2005. The sexual differentiation of Cannabis sativa L.: A morphological and molecular study. Euphytica 140(1-2): 95-106. Retrieved on 25 Feb 2007.
2. Bouquet, R.J.1950. Cannabis. United Nations Office on Drugs and Crime. Retrieved on 5 Oct 2006.
3. K. H. Ratio et al. Current medicinal chemistry 2005, 12, (1217/1237). 4. Pionelli, D, The molecular logic of endocannabinoid signaling. Nat. Rev.
Neurosci. 2003, 4, 873-884.
5. Demuth DG, Molleman A. Cannabinoid signaling. Life Sci. 2006;78:549-563.
6. Lu, Q.; Striker, A.; Lu, Q.; Maguire, G. Vis. Neurosci., 2000, 17, 91. 7. Casanova, M. L.; Blazquez, C.; Martinez-Palacio, J.; Villanueva, C.; Ferdandez-
Acenero, M.J., Huffaman, J. Clin. Invest., 2003, 111, 43.
8. Sanchez, C.; Ceballos, M. L., Gomez del Pulgar, T.; Rueda, D.; Cancer
Res., 2001, 61, 5784.
9. Elphick, M. R.; Satou, Y.; Satoh, N. Gene, 2003, 302, 95.
10. Cota D, Woods SC. The role of the endocannabinoid system in the regulation of energy homeostasis. Curr Opin Endocrinol Diabetes. 2005;12:338-351.
11. Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R. The emerging role of the endocannabinoid system in endocrine regulation and energy balance.
Endocr Rev. 2006;27:73-100.
12. Nie, J.; Lewis, D.L. Neuroscience., 2001, 107, 161. 13. Feng, W. ; Song, Z.H. FEBS Lett., 2001 , 501, 166.
14. Feng, W. ; Song, Z.H. Biochem. Pharmacol., 2003, 65, 1077.
15. Howlett, A. C.; Barth, F.; Bonner, T. I:; Cabral, G.; Casellas, P.; Devane, W. A.; Felder, C. C.; Pharmacol. Rev., 2002, 54, 161.
16. Prolaro, D.; Massi, P.; Rubino, T.; Monti, E. Prostaglandins Leukot.
Essent. Fatty Acids, 2002, 66, 319.
17. Kiss, Z. FEBS Lett., 1999, 447, 209. 23. Hunter, S. A.; Burstein, S.; Renzulli, L. Neurochem. Res., 1996, 11, 1273.
18. Hunter, S. A.; Burstein, S.; Renzulli, L. Neurochem. Res., 1996, 11, 1273.
19. Chan, G. C.; Hinds, T.; Impey, S.; Stom, D. R. J.Neurosci., 1998, 18, 5322.
20. Hla, T.; Bishop-Bailey, D.; Liu, C. H.; Schaefers, H.J.; Trifan, O. C. Int.J. Biochem. Cell Biol., 1999, 31, 551.
21. Ramer, R.; Brune, K.; Pahl, A.; Hinz, B. Biochem. Biophys. Res. Comun., 2001, 286, 1144.
22. Ananda P., Whitesideb G., J. Fowlerc C., G. Hohmannd A.; Brain
research reviews. 2009; 60: 255 – 266.
23. Hohmann, A.G., 2002. Spinal and peripheral mechanisms of cannabinoid antinociception: behavioral, neurophysiological and neuroanatomical perspectives. Chem. Phys. Lipids 121, 173–190.
24.Calignano, A., La Rana, G., Giuffrida, A., Piomelli, D., 1998. Control of pain initiation by endogenous cannabinoids. Nature 394, 277–281.
25.Fride, E., Feigin, C., Ponde, D.E., Breuer, A., Hanus, L., Arshavsky, N., Mechoulam, R., 2004. (+)-Cannabidiol analogues which bind cannabinoid receptors but exert peripheral activity only. Eur. J. Pharmacol. 506, 179– 188.
26. Dziadulewicz, E.K., Bevan, S.J., Brain, C.T., Coote, P.R., Culshaw, A.J., Davis, A.J., Edwards, L.J., Fisher, A.J., Fox, A.J., Gentry, C., Groarke, A., Hart, T.W., Huber, W., James, I.F., Kesingland, A., La Vecchia, L., Loong, Y., Lyothier, I., McNair, K., O, Farrell, C., Peacock, M., Portmann, R., Schopfer, U., Yaqoob, M., Zadrobilek, J., 2007. Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl) methanone: a potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration. J. Med. Chem. 50, 3851– 3856.
27. Beltramo M, Bernardini N, Bertorelli R, et al.. CB2 receptors-mediated antihyperalgesia: possibile direct involvement of neural mechanisms. Eur J
Neurosci. 2006; 23: 1530-1538.
28. Ibrahim MM., Rude Ml., Stagg NJ., et al.. CB2 Cannabinoid receptor mediation of antinociception. Pain. 2006; 122: 36-42.
29. Richardson JD., Kilo S., et al.. Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptorss. Pain. 1998; 75: 111-119.
30. Kelly S., Jhaveri MD., Sagar DR., et al.. Activation of pheripheral cannabinoid CB1 receptorss inhibits mechanically evoked responses of spinal neurons in noninflamed rats and rats with hindpaw inflammation.
Eur J Neurosci. 2003; 18: 2239-2243.
31. Demuth DG, Molleman A. Cannabinoid signaling. Life Sci. 2006;78:549-563.
32. Fernandez-Ruiz, J. et al.(2005) Cannabinoids in neurodegeration and neuroprotection in Cannabinoids as therapeutics pp 79-109.
33. Romero, J. et al (2002) The endogenous cannabinoid system and the basal ganglia, biochemical, pharmacological and therapeutic aspects.
34. Mechoulam, R. et al. (2002) Cannabinoids and brain injury: therapeutic implications. Trends Mol. Med. 8, 58-61.
35. Diego Centonze, Alessandro Finazzi-Agrò, Giorgio Bernardi and Mauro Maccarrone. (2007) The endocannabinoid system in targeting inflammatory neurodegenerative diseases. Trends in Pharmacological Sciences 28.(4), 180-187.
36. C Benito, RM Tolo´n, MR Pazos, E Nu´n˜ez, AI Castillo, and J Romero (2008) Cannabinoid CB2 receptorss in human brain inflammation. British
Journal of Pharmacology 153, 277–285.
37. Javier Fern´andez-Ruiz, Mar´ıa Ruth Pazos, Mois´es Garc´ıa-Arencibia, Onintza Sagredo, Jos´e A. Ramos (2008) Role of CB2 receptorss in neuroprotective effects of cannabinoids. Molecular and Cellular
Endocrinology 286S, S91–S96.
38. Diego Centonze, Silvia Rossi, Alessandro Finazzi-Agrò, Giorgio Bernardi and Mauro Maccarrone (2007) The (endo)cannabinoid system in multiple sclerosis and amyotrophic lateral sclerosis. International Review of
Neurobiology 82, 171-186.
39. J Guindon and AG Hohmann (2008) Cannabinoid CB2 receptorss: a therapeutic target for the treatment of inflammatory and neuropathic pain.
British Journal of Pharmacology 153, 319–334.
40. Sauchez, C. et al. (2001) Inhibition of glioma growth in vivo by selective activation of the CB2 cannabinoid receptor. Cancer Res. 61, 5784-5789.
41. Guzman, M. (2003) Cannabinoids: potential anticancer agents. Nat.
Rev. Cancer 3, 745-755.
42. Carracedo, A. et al. (2006) Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes Cancer Res. 66, 6748-6755.
43. Diego Centonze, Silvia Rossi, Alessandro Finazzi-Agrò, Giorgio Bernardi and Mauro Maccarrone (2007) The (endo)cannabinoid system in multiple sclerosis and amyotrophic lateral sclerosis. International Review of
Neurobiology 82, 171-186.
44. J Guindon and AG Hohmann (2008) Cannabinoid CB2 receptorss: a therapeutic target for the treatment of inflammatory and neuropathic pain.
British Journal of Pharmacology 153, 319–334.
45.Weinreb, R.N. and Khaw, P.T. (2004) Primary open-angle glaucoma.
Lancet, 363: 1711–1720.
46. Heijl, A., Leske, M.C., Bengtsson, B., Hyman, L. and Hussein, M. (2002) Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch. Ophthalmol., 120: 1268– 1279.
47.Kass, M.A., Heuer, D.K., Higginbotham, E.J., Johnson, C.A., Keltner, J.L., Miller, J.P., Parrish, R.K., 2nd., Wilson, M.R. and Goedon, M.O. (2002) The ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevent the onset of primary open-angle glaucoma. Arch. Ophthalmol., 120(6): 701– 713.
48. Collaborative Normal Tension Glaucoma Study Group. (1998) Comparison of glaucomatous progression between untreated patients with normal tension glaucoma and patients with therapeutically reduced intraocular pressure. Am. J. Ophthamol., 126: 498–505.
49. Nucci, C., Tartaglione, R., Rombola, L., Morrone, L.A., Fazzi, E. and Bagetta, G. (2005b) Neurochemical evidence to implicate elevated glutamate in the mechanisms of high intraocular pressure (IOP)-induced retinal ganglion cell death in rat. Neurotoxicology, 26: 935-941.
50.Louzada-Junior, P., Dias, J.J., Santos, W.F., Lachat, J.J., Bradford, H.F. and Coutinho-Netto, J. (1992) Glutamate release in experimental ischaemia
of the retina: an approach using microdialysis. J. Neurochem., 59(1): 358– 363.
51. Dreyer, E.B., Zurakowsky, D., Schumer, R.A., Podos, S.M. and Lipton, S.A. (1996) Elevated glutamate in the vitreous of humans and monkeys with glaucoma. Arch. Ophthalmol., 114(3): 299–305.
52.McIntosh, B.T., Hudson, B., Yegorova, S., Jollimore, C.A.B. and Kelly, M.E.M. (2007) Agonist-dependent cannabinoid receptor signalling in human trabecular meshwork k cells. Br. J. Pharmacol., 152: 1111–1120. 53. He, F. and Song, Z.H. (2007) Molecular and cellular changes induced by the activation of CB2 cannabinoid receptors in trabecular meshwork cells. Mol. Vis., 13: 1348–1356.
54.Straiker, A., Maguire, G., Makie, K. and Lindsey, J (1999) Localization of cannabinoid CB1 receptorss in the human anterior eye and retina. Invest.
Ophthalmol. Vis. Sci., 40: 2442–2448.
55. Tomida, I., Azuara-Blanco, A., House, H., Flint, M., Pertwee, R.G. and Robson, P.J. (2006) Effect of sublingual application of cannabinoids on intraocular pressure: a pilot study. J. Glaucoma, 15: 349–353.
56. Hepler, R.S. and Frank, I.R. (1971) Marihuana smoking and intraocular pressure (letter). JAMA, 217: p. 1392.
57. Brown, B., Adams, A.J. and Haegerstrom-Portnoy, G. (1977) Pupil size after use of marijuana and alcohol. Am. J. Ophthalmol., 83(3): 350–354. 58. Porcella, A., Maxia, C.H., Gessa, G.L. and Pani, L. (2001) The synthetic cannabinoids WIN-55,212-2 decreases the intraocular pressure in human glaucoma resistant to conventional therapies. Eur. J. Neurosci., 13: 409–412. 59Pate, D.W., Ja¨ rvinen, K., Urtti, A., Mahadevan, V. and Jarvinen, T. (1998) Effect of the CB1 receptors antagonist SR 141716A on cannabinoids induced ocular hypotension in normotensive rabbits. Life Sci., 63: 2181–2188.
59. Laine, K., Jarvinen, K., Mechoulam, R., Breuer, A. and Jarvinen, T. (2002a) Comparison of the enzymatic stability and intraocular pressure effects of 2-arachidonylglycerol and noladin ether, a novel putative endocannabinoid. Invest. Ophthalmol. Vis. Sci., 43: 3216–32122.
60. Laine, K., Jarvinen, K., Mechoulam, R., Breuer, A. and Jarvinen, T. (2002a) Comparison of the enzymatic stability and intraocular pressure effects of 2-arachidonylglycerol and noladin ether, a novel putative endocannabinoid. Invest. Ophthalmol. Vis. Sci., 43: 3216–32122.
61. Tomida, I., Pertwee, R.G. and Azuara-Blanco, A. (2004) Cannabinoids and glaucoma. Br. J. Ophthalmol., 88: 708–713.
62. Lograno, M.D. and Romano, M.R. (2004) Cannabinoid agonists induce contractile responses through Gi/o-dependent activation of phospholipase C in the bovine ciliary muscle. Eur. J. Pharmacol., 494: 55–62.
63. Van der Stelt, M. and Di Marzo, V. (2005) Cannabinoid receptors and their role in neuroprotection. Neuromolecular Med., 7(1–2): 37–50.
64. Weinreb, R.N. and Khaw, P.T. (2004) Primary open-angle glaucoma.
Lancet, 363: 1711–1720.
65. Baker, D., Pryce, G., Giovannoni, G. and Thompson, A.J. (2003) The therapeutic potential of cannabis. Lancet Neurol., 2(5): 291–298.
65a. Carlo Nucci, Monica Bari, Arnoldo Spanò, MariaTiziana Corasaniti, Giacinto Bagetta, Mauro Maccarrone and Luigi Antonio Morrone. Potential roles of (endo)cannabinoids in the treatment of glaucoma: from intraocular pressure control to neuroprotection.Progress in Brain Research, Vol. 173, chapter 31.
66 . Manera C. et al, J. Med. Chem: 2006, 49, 5497-5957. 67. Manera C. et al, J. Med. Chem: 2009, 52, 3644-51.
68. Tuccinardi, T.; Ferrarini, P. L.; Manera, C.; Ortore, G.; Saccomanni, G.; Martinelli, A. Cannabinoid CB2/CB1 selectivity. Receptor modelling and automated docking analysis. J. Med. Chem. 2006, 49, 984-994.
